NovoCure annual current ratio
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
NovoCure Current Ratio Growth & History (NVCR)
NovoCure's current ratio was 2.90 for fiscal 2025.
View full NovoCure company overviewNovoCure annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.90 | 1.43 | +98.04% |
| 2024 | 2024-12-31 | 1.46 | −4.31 | −74.67% |
| 2023 | 2023-12-31 | 5.78 | −1.23 | −17.51% |
| 2022 | 2022-12-31 | 7.00 | −0.53 | −7.01% |
| 2021 | 2021-12-31 | 7.53 | −1.27 | −14.42% |
| 2020 | 2020-12-31 | 8.80 | 3.70 | +72.58% |
| 2019 | 2019-12-31 | 5.10 | 0.12 | +2.40% |
| 2018 | 2018-12-31 | 4.98 | 0.09 | +1.94% |
| 2017 | 2017-12-31 | 4.88 | −2.22 | −31.23% |
| 2016 | 2016-12-31 | 7.10 | −3.17 | −30.84% |
| 2015 | 2015-12-31 | 10.27 | 3.94 | +62.21% |
| 2014 | 2014-12-31 | 6.33 | — | — |
NovoCure quarterly current ratio
Q4.14
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.89 | 1.45 | +100.20% |
| Q1 2026 | 2026-03-31 | 2.90 | 1.44 | +98.10% |
| Q4 2025 | 2025-12-31 | 2.90 | 1.43 | +98.04% |
| Q3 2025 | 2025-09-30 | 1.55 | 0.06 | +3.76% |
| Q2 2025 | 2025-06-30 | 1.45 | −5.01 | −77.63% |
| Q1 2025 | 2025-03-31 | 1.47 | −4.79 | −76.58% |
| Q4 2024 | 2024-12-31 | 1.46 | −4.31 | −74.67% |
| Q3 2024 | 2024-09-30 | 1.49 | −5.18 | −77.65% |
| Q2 2024 | 2024-06-30 | 6.46 | −0.64 | −9.01% |
| Q1 2024 | 2024-03-31 | 6.26 | −1.06 | −14.51% |
| Q4 2023 | 2023-12-31 | 5.78 | −1.23 | −17.51% |
| Q3 2023 | 2023-09-30 | 6.67 | −1.15 | −14.66% |
| Q2 2023 | 2023-06-30 | 7.10 | −0.98 | −12.18% |
| Q1 2023 | 2023-03-31 | 7.32 | −1.14 | −13.43% |
| Q4 2022 | 2022-12-31 | 7.00 | −0.53 | −7.01% |
| Q3 2022 | 2022-09-30 | 7.81 | −0.77 | −8.96% |
| Q2 2022 | 2022-06-30 | 8.08 | −0.91 | −10.15% |
| Q1 2022 | 2022-03-31 | 8.46 | −0.73 | −7.98% |
| Q4 2021 | 2021-12-31 | 7.53 | −1.27 | −14.42% |
| Q3 2021 | 2021-09-30 | 8.58 | 4.56 | +113.37% |
| Q2 2021 | 2021-06-30 | 9.00 | 3.27 | +57.01% |
| Q1 2021 | 2021-03-31 | 9.19 | 3.70 | +67.41% |
| Q4 2020 | 2020-12-31 | 8.80 | 3.70 | +72.58% |
| Q3 2020 | 2020-09-30 | 4.02 | −1.04 | −20.52% |
| Q2 2020 | 2020-06-30 | 5.73 | 0.70 | +13.94% |
| Q1 2020 | 2020-03-31 | 5.49 | 0.76 | +16.01% |
| Q4 2019 | 2019-12-31 | 5.10 | 0.12 | +2.40% |
| Q3 2019 | 2019-09-30 | 5.06 | −1.11 | −18.01% |
| Q2 2019 | 2019-06-30 | 5.03 | −1.38 | −21.50% |
| Q1 2019 | 2019-03-31 | 4.73 | −1.59 | −25.13% |
| Q4 2018 | 2018-12-31 | 4.98 | 0.09 | +1.94% |
| Q3 2018 | 2018-09-30 | 6.17 | 0.27 | +4.59% |
| Q2 2018 | 2018-06-30 | 6.41 | −0.32 | −4.72% |
| Q1 2018 | 2018-03-31 | 6.32 | −1.31 | −17.16% |
| Q4 2017 | 2017-12-31 | 4.88 | −2.22 | −31.23% |
| Q3 2017 | 2017-09-30 | 5.90 | −3.23 | −35.40% |
| Q2 2017 | 2017-06-30 | 6.72 | −0.06 | −0.82% |
| Q1 2017 | 2017-03-31 | 7.63 | −1.33 | −14.85% |
| Q4 2016 | 2016-12-31 | 7.10 | −3.17 | −30.84% |
| Q3 2016 | 2016-09-30 | 9.14 | 3.01 | +49.08% |
| Q2 2016 | 2016-06-30 | 6.78 | — | — |
| Q1 2016 | 2016-03-31 | 8.96 | — | — |
| Q4 2015 | 2015-12-31 | 10.27 | 3.94 | +62.21% |
| Q3 2015 | 2015-09-30 | 6.13 | — | — |
| Q4 2014 | 2014-12-31 | 6.33 | — | — |
NovoCure current ratio trends
Over the last five fiscal years, NovoCure's current ratio decreased from 8.80 to 2.90, a change of −5.90. The latest reported quarter, Q2 2026, shows 2.89.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗Community posts
Novocure raises annual revenue and EBITDA targets as patient numbers grow
Novocure ($NVCR) lifted its 2026 revenue forecast to $736–$743 million from $710–$725 million and its adjusted EBITDA outlook to $24–$34 million from $0–$15 million. Third-quarter 2026 revenue increased 16% to $193.4 million, supported by 1 ...
